Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P34896

UPID:
GLYC_HUMAN

ALTERNATIVE NAMES:
Glycine hydroxymethyltransferase; Serine methylase

ALTERNATIVE UPACC:
P34896; B4DPM9; D3DXD0; Q96HY0; Q9UMD1; Q9UMD2

BACKGROUND:
The enzyme Serine hydroxymethyltransferase, cytosolic, with alternative names Glycine hydroxymethyltransferase and Serine methylase, is essential for the metabolic pathway that converts serine to glycine. This process is vital for maintaining the balance of amino acids in the body, as evidenced by its unique identifier P34896.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Serine hydroxymethyltransferase, cytosolic reveals potential for groundbreaking therapeutic interventions. Given its central role in amino acid metabolism, targeting this enzyme could lead to innovative treatments for metabolic diseases, marking a significant step forward in medical science.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.